The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

References

• Lawrence C, Lipton RB, Lowy FD, Coyle PK. Seronegative chronic relapsing neuroborreliosis. Eur Neurol. 1995;35:113–117. doi:10.1159/000117104
   PubMed Web of Science ®Google Scholar
• Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990;323:1438–1444. doi:10.1056/NEJM199011223232102
   PubMed Web of Science ®Google Scholar
• Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med. 1994;121:560–567. doi:10.7326/0003-4819-121-8-199410150-00002
   PubMed Web of Science ®Google Scholar
• Liegner KB, Rosenkilde C, Campbell G, et al. Culture confirmed treatment failure of cefotaxime and minocycline in a case of Lyme meningoencephalomyelitis in the United States. Proceedings of the Program and Abstracts of the 5th International Conference on Lyme Borreliosis. Arlington, VA, USA; 1992.
   Google Scholar
• Embers ME, Barthold SW, Borda JT, et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One. 2012;7(1):e29914. PMID: 22253822; PMCID: PMC3256191. doi:10.1371/journal.pone.0029914
   PubMed Web of Science ®Google Scholar
• Embers ME, Hasenkampf NR, Jacobs MB, et al. Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding. PLoS One. 2017;12(12):e0189071. PMID: 29236732; PMCID: PMC5728523. doi:10.1371/journal.pone.0189071
   PubMed Web of Science ®Google Scholar
• Hodzic E, Imai D, Feng S, Barthold SW. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice. PLoS One. 2014;9(1):e86907. PMID: 24466286; PMCID: PMC3900665. doi:10.1371/journal.pone.0086907
   PubMed Web of Science ®Google Scholar
• Oksi J, Kalimo H, Marttila RJ, et al. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of the literature. Brain. 1996;119:2143–2154. PMID: 9010017. doi:10.1093/brain/119.6.2143
   PubMed Web of Science ®Google Scholar
• Bransfield RC. Neuropsychiatric Lyme borreliosis: an overview with a focus on a specialty psychiatrist’s clinical practice. Healthcare. 2018;6(3):104. PMID: 30149626; PMCID: PMC6165408. doi:10.3390/healthcare6030104
   Web of Science ®Google Scholar
• Bransfield RC. Lyme Disease, comorbid tick-borne diseases, and neuropsychiatric disorders. Psychiatr Times. 2007;24(14):59–61.
   Google Scholar
• Fallon BA, Nields JA, Burrascano JJ, et al. The neuropsychiatric manifestations of Lyme borreliosis. Psychiatr Q. 1992;63(1):95–117. doi:10.1007/BF01064684
   PubMedGoogle Scholar
• Fallon BA, Nields JA. Lyme disease: a neuropsychiatric illness. Am J Psychiatry. 1994;151(11):1571–1583. PMID: 1438607. doi:10.1007/BF01064684
   PubMed Web of Science ®Google Scholar
• Fallon BA, Kochevar JM, Gaito A, Nields JA. The underdiagnosis of neuropsychiatric Lyme disease in children and adults. Psychiatr Clin N Am. 1998;21(3):693–703. doi:10.1016/s0193-953x(05)70032-0
   PubMed Web of Science ®Google Scholar
• Bransfield RC. Aggressiveness, violence, homicidality, homicide, and Lyme disease. Neuropsychiatr Dis Treat. 2018;14:693–713. PMID: 29576731; PMCID: PMC5851570. doi:10.2147/NDT.S155143
   PubMed Web of Science ®Google Scholar
• Mattingley DW, Koola MM. Association of Lyme disease and schizoaffective disorder, bipolar type: is it inflammation mediated? Indian J Psychol Med. 2015;37(2):243–246. PMID: 25969618; PMCID: PMC4418265. doi:10.4103/0253-7176.155660
   PubMedGoogle Scholar
• Greenberg R. Tick-borne infections and pediatric bipolar disorder. Neurol Psychiatry Brain Res. 2015;22:11. doi:10.1016/j.npbr.2015.12.025
   Google Scholar
• Breitschwerdt EB, Sontakke S, Hopkins S. Neurological manifestations of bartonellosis in immunocompetent patients: a composite of reports from 2005–2012. J Neuroparasitol. 2012;3:1–15. doi:10.4303/jnp/235640
   Google Scholar
• Flegr J, Preiss M, Balátová P. Depressiveness and neuroticism in bartonella seropositive and seronegative subjects-preregistered case-controls study. Front Psychiatry. 2018;9:314. PMID: 30061846; PMCID: PMC6055045. doi:10.3389/fpsyt.2018.00314
   PubMed Web of Science ®Google Scholar
• Breitschwerdt EB, Greenberg R, Maggi RG, et al. Bartonella henselae bloodstream infection in a boy with pediatric acute-onset neuropsychiatric syndrome. J Cent Nerv Syst Dis. 2019;11:1179573519832014. PMID: 30911227; PMCID: PMC6423671. doi:10.1177/1179573519832014
   Web of Science ®Google Scholar
• Breitschwerdt EB, Bradley JM, Maggi RG, et al. Bartonella associated cutaneous lesions (BACL) in people with neuropsychiatric symptoms. Pathogens. 2020;9(12):1023. PMID: 33291688; PMCID: PMC7761945. doi:10.3390/pathogens9121023
   PubMed Web of Science ®Google Scholar
• Greenberg R. Infections and childhood psychiatric disorders: tick-borne illness and bipolar disorder in youth. Bipolar Disord. 2017;3:113. doi:10.4172/2472-1077.10001
   Google Scholar
• Sherr VT. Human babesiosis--an unrecorded reality. Absence of formal registry undermines its detection, diagnosis and treatment, suggesting need for immediate mandatory reporting. Med Hypotheses. 2004;63(4):609–615. PMID: 15325004. doi:10.1016/j.mehy.2004.04.006
   PubMed Web of Science ®Google Scholar
• Banerjee B, Petersen K. Psychosis following mycoplasma pneumonia. Mil Med. 2009;174(9):1001–1004. PMID: 19780379. doi:10.7205/milmed-d-00-8209
   PubMed Web of Science ®Google Scholar
• Moor S, Skrine H. Psychosis in mycoplasma infection. Postgrad Med J. 1989;65(760):96–97. doi:10.1136/pgmj.65.760.96
   PubMed Web of Science ®Google Scholar
• Ercan TE, Ercan G, Severge B, et al. Mycoplasma pneumoniae infection and obsessive-compulsive disease: a case report. J Child Neurol. 2008;23(3):338–340. PMID: 18079308. doi:10.1177/0883073807308714
   PubMed Web of Science ®Google Scholar
• Becker MA, Cannon J, Certa K. A case of mycoplasma pneumoniae encephalopathy presenting as mania. J Acad Consult Liaison Psychiatry. 2021;62(1):150–154. doi:10.1016/j.psym.2020.02.004
   PubMedGoogle Scholar
• Toufexis MD, Hommer R, Gerardi DM, et al. Disordered eating and food restrictions in children with PANDAS/PANS. J Child Adolesc Psychopharmacol. 2015;25(1):48–56. PMID: 25329522; PMCID: PMC4340640. doi:10.1089/cap.2014.0063
   PubMed Web of Science ®Google Scholar
• Piras C, Pintus R, Pruna D, et al. pediatric acute-onset neuropsychiatric syndrome and Mycoplasma Pneumoniae infection: a case report analysis with a metabolomics approach. Curr Pediatr Rev. 2020;16(3):183–193. PMID: 31642785; PMCID: PMC8193809. doi:10.2174/1573396315666191022102925
   PubMed Web of Science ®Google Scholar
• Frankovich J, Thienemann M, Rana S, Chang K. Five youth with pediatric acute-onset neuropsychiatric syndrome of differing etiologies. J Child Adolesc Psychopharmacol. 2015;25(1):31–37. PMID: 25695942; PMCID: PMC4442568. doi:10.1089/cap.2014.0056
   PubMed Web of Science ®Google Scholar
• Miklossy J. Chronic or late Lyme neuroborreliosis: analysis of evidence compared to chronic or late neurosyphilis. Open Neurol J. 2012;6:146–157. doi:10.2174/1874205X01206010146
   PubMedGoogle Scholar
• Back T, Grünig S, Winter Y, et al. Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. J Neurol. 2013;260:1569–1575. doi:10.1007/s00415-013-6831-4
   PubMed Web of Science ®Google Scholar
• Bransfield RC. The psychoimmunology of Lyme/Tick-Borne diseases and its association with neuropsychiatric symptoms. Open Neurol J. 2012;688–693. doi:10.2174/1874205X01206010088
   Google Scholar
• Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis. 2010;37(3):534–541. PMID: 19944760. doi:10.1016/j.nbd.2009.11.016
   PubMed Web of Science ®Google Scholar
• Benros ME, Waltoft BL, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013;70(8):812–820. doi:10.1001/jamapsychiatry.2013.1111
   PubMed Web of Science ®Google Scholar
• Chang K, Frankovich J, Cooperstock M, et al. PANS Collaborative Consortium. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol. 2015;25(1):3–13. PMID: 25325534; PMCID: PMC4340805. doi:10.1089/cap.2014.0084
   PubMed Web of Science ®Google Scholar
• Calaprice D, Tona J, Murphy TK. Treatment of pediatric acute-onset neuropsychiatric disorder in a large survey population. J Child Adolesc Psychopharmacol. 2018;28(2):92–103. PMID: 28832181; PMCID: PMC5826468. doi:10.1089/cap.2017.0101
   PubMed Web of Science ®Google Scholar
• Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. PMID: 33146667; PMCID: PMC7643046. doi:10.1001/jamapsychiatry.2020.3285
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740. PMID: 17196053. doi:10.4088/jcp.v67n1110
   PubMed Web of Science ®Google Scholar
• Khan AJ, Bradley E, O’Donovan A, Woolley J. Psilocybin for trauma-related disorders. Curr Top Behav Neurosci. 2022;56:319–332. PMID: 35711024. doi:10.1007/7854_2022_366
   PubMedGoogle Scholar
• Bogadi M, Kaštelan S. A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. Croat Med J. 2021;62(5):528–530. PMID: 34730895; PMCID: PMC8596485. doi:10.3325/cmj.2021.62.528
   PubMed Web of Science ®Google Scholar
• Yu CL, Yang FC, Yang SN, et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investig. 2021;18(10):958–967. PMID: 34619818; PMCID: PMC8542741. doi:10.30773/pi.2021.0209
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. PMID: 27909165; PMCID: PMC5367557. doi:10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–992. doi:10.1177/0269881114548296
   PubMed Web of Science ®Google Scholar
• Ling S, Ceban F, Lui LMW, et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022;36(1):17–30. PMID: 34791625. doi:10.1007/s40263-021-00877-y
   PubMed Web of Science ®Google Scholar
• Nkadimeng SM, Nabatanzi A, Steinmann CML, Eloff JN. Phytochemical, cytotoxicity, antioxidant and anti-inflammatory effects of psilocybe natalensis magic mushroom. Plants. 2020;9(9):1127. PMID: 32878164; PMCID: PMC7570254. doi:10.3390/plants9091127
   Google Scholar
• Nkadimeng SM, Steinmann CML, Eloff JN. Anti-inflammatory effects of four psilocybin-containing magic mushroom water extracts in vitro on 15-lipoxygenase activity and on lipopolysaccharide-induced cyclooxygenase-2 and inflammatory cytokines in human U937 macrophage cells. J Inflamm Res. 2021;14:3729–3738. PMID: 34385833; PMCID: PMC8352634. doi:10.2147/JIR.S317182
   PubMed Web of Science ®Google Scholar
• Kubera M, Maes M, Kenis G, et al. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005;134(3):251–258. PMID: 15892984. doi:10.1016/j.psychres.2004.01.014
   PubMed Web of Science ®Google Scholar
• Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363–375. PMID: 30102081. doi:10.1080/09540261.2018.1481827
   PubMed Web of Science ®Google Scholar
• Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest. 1986;78(4):934–939. PMID: 3531237; PMCID: PMC423723. doi:10.1172/JCI112683
   PubMed Web of Science ®Google Scholar
• Steere AC. Lyme arthritis: correlation of serum and cryoglobulin IgM with activity, and serum IgG with remission. Arthritis Rheum. 1979;22(5):471–483. PMID: 109097. doi:10.1002/art.1780220506
   PubMed Web of Science ®Google Scholar
• Owen DC. Is Lyme disease always polymicrobial?--The jigsaw hypothesis. Med Hypotheses. 2006;67(4):860–864. PMID: 16814477. doi:10.1016/j.mehy.2006.03.046
   PubMed Web of Science ®Google Scholar
• Garg K, Meriläinen L, Franz O, et al. Evaluating polymicrobial immune responses in patients suffering from tick-borne diseases. Sci Rep. 2018;8:15932. doi:10.1038/s41598-018-34393-9
   PubMed Web of Science ®Google Scholar
• Berghoff W. Chronic Lyme disease and co-infections: differential diagnosis. Open Neurol J. 2012;6:158–178. PMID: 23400696; PMCID: PMC3565243. doi:10.2174/1874205X01206010158
   PubMedGoogle Scholar
• Sinco G, Bergamo S. Impact of co-infections in Lyme disease. Open Dermatol J. 2016;10:255–261. doi:10.2174/1874372201610010055
   Google Scholar
• Moutailler S, Valiente Moro C, Vaumourin E, et al. Co-infection of ticks: the rule rather than the exception. PLoS Negl Trop Dis. 2016;10(3):e0004539. PMID: 26986203; PMCID: PMC4795628. doi:10.1371/journal.pntd.0004539
   PubMed Web of Science ®Google Scholar
• Adelson ME, Rao RV, Tilton RC, et al. Prevalence of Borrelia burgdorferi, Bartonella spp., Babesia microti, and Anaplasma phagocytophila in Ixodes scapularis ticks collected in Northern New Jersey. J Clin Microbiol. 2004;42(6):2799–2801. PMID: 15184475; PMCID: PMC427842. doi:10.1128/JCM.42.6.2799-2801.2004
   PubMed Web of Science ®Google Scholar
• Tokarz R, Tagliafierro T, Sameroff S, et al. Microbiome analysis of Ixodes scapularis ticks from New York and Connecticut. Ticks Tick Borne Dis. 2019;10(4):894–900. doi:10.1016/j.ttbdis.2019.04.011
   PubMed Web of Science ®Google Scholar
• Holden K, Boothby J, Kasten R, Chomel B. Co-detection of Bartonella henselae, Borrelia burgdorferi, and Anaplasma phagocytophilum in Ixodes pacificus Ticks from California, USA. Vector Borne Zoonotic Dis. 2006;6:99–102. PMID: 16584332. doi:10.1089/vbz.2006.6.99
   PubMed Web of Science ®Google Scholar
• Saplkoglu Y. Nov 25, 2019. FDA Calls Psychedelic Psilocybin a ‘Breakthrough Therapy’ for Severe Depression. Available from: https://www.livescience.com/psilocybin-depression-breakthrough-therapy.html. Accessed February 26, 2023.
   Google Scholar
• Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol. 2019;22(7):426–434. PMID: 31152167; PMCID: PMC6600464. doi:10.1093/ijnp/pyz029
   PubMed Web of Science ®Google Scholar
• Reddit. Microdosing: sub-threshold dosing of psychedelic drugs for self-improvement, therapy or well-being. Available from: https://www.reddit.com/r/microdosing/. Accessed October 10, 2022.
   Google Scholar
• Oilove, M. July 15, 2022. More States May Legalize Psychedelic Mushrooms. Available from: https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2022/07/15/more-states-may-legalize-psychedelic-mushrooms. Accessed February 26, 2023.
   Google Scholar
• Rootman JM, Kryskow P, Harvey K, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021;11(1):22479. PMID: 34795334; PMCID: PMC8602275. doi:10.1038/s41598-021-01811-4
   PubMed Web of Science ®Google Scholar
• Lea T, Amada N, Jungaberle H. Psychedelic microdosing: a subreddit analysis. J Psychoactive Drugs. 2020;52:101–112. doi:10.1080/02791072.2019
   PubMed Web of Science ®Google Scholar
• Lea T, Amada N, Jungaberle H, et al. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacol. 2020;237:1521. doi:10.1007/s00213-020-05477-0
   Web of Science ®Google Scholar
• Fadiman J. The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys. New York: Simon and Schuster; 2021.
   Google Scholar
• Johnstad PG. Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Stud Alcohol Drugs. 2018;35(1):39–51. doi:10.1177/1455072517753339
   Web of Science ®Google Scholar
• Kuypers KPC. The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol. 2020;10:2045125320950567. PMID: 32922736; PMCID: PMC7457631. doi:10.1177/2045125320950567
   Web of Science ®Google Scholar
• Cameron LP, Nazarian A, Olson DE. Psychedelic microdosing: prevalence and subjective effects. J Psychoactive Drugs. 2020;52:113–122. doi:10.1080/02791072.2020.1718250
   PubMed Web of Science ®Google Scholar
• Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14:e0211023. doi:10.1371/journal.pone.0211023
   PubMed Web of Science ®Google Scholar
• Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021;10(e62878). PMID: 33648632; PMCID: PMC7925122. doi:10.7554/eLife.62878
   PubMedGoogle Scholar
• Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12(307). doi:10.1038/s41398-022-02039-0
   PubMedGoogle Scholar
• Coppola M, Bevione F, Mondola R. Psilocybin for treating psychiatric disorders: a psychonaut legend or a promising therapeutic perspective? J Xenobiot. 2022;12(1):41–52. PMID: 35225956; PMCID: PMC8883979. doi:10.3390/jox12010004
   PubMed Web of Science ®Google Scholar
• Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A. 2021;118(17):e2022489118. PMID: 33850049; PMCID: PMC8092378. doi:10.1073/pnas.2022489118
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuysen MFI, Babler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neuroreport. 1998;9:3897–3902. doi:10.1097/00001756-199812010-00024
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HAT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11C] raclopride. Neuropsychopharmacol. 1999;112:424–434. doi:10.1016/S0893-133X(98)00108-0
   Google Scholar
• Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett. 2020;228:45–54. PMID: 33035575. doi:10.1016/j.imlet.2020.10.001
   PubMed Web of Science ®Google Scholar
• Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434–1452. PMID: 20855349. doi:10.1177/0269881110382466
   PubMed Web of Science ®Google Scholar
• Anderson T, Petranker R, Christopher A, et al. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J. 2019;16(1):43. PMID: 31288862; PMCID: PMC6617883. doi:10.1186/s12954-019-0308-4
   PubMedGoogle Scholar